"Genes, BRCA1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.
| Descriptor ID |
D019398
|
| MeSH Number(s) |
G05.360.340.024.340.375.249.100 G05.360.340.024.340.415.400.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Genes, BRCA1".
Below are MeSH descriptors whose meaning is more specific than "Genes, BRCA1".
This graph shows the total number of publications written about "Genes, BRCA1" by people in this website by year, and whether "Genes, BRCA1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 3 | 3 | 6 |
| 2001 | 4 | 0 | 4 |
| 2002 | 5 | 1 | 6 |
| 2003 | 2 | 1 | 3 |
| 2004 | 4 | 1 | 5 |
| 2005 | 8 | 0 | 8 |
| 2006 | 3 | 4 | 7 |
| 2007 | 4 | 2 | 6 |
| 2008 | 6 | 4 | 10 |
| 2009 | 4 | 1 | 5 |
| 2010 | 3 | 0 | 3 |
| 2011 | 6 | 2 | 8 |
| 2012 | 3 | 2 | 5 |
| 2013 | 2 | 0 | 2 |
| 2014 | 7 | 3 | 10 |
| 2015 | 1 | 3 | 4 |
| 2016 | 5 | 3 | 8 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 2 | 4 |
| 2021 | 1 | 3 | 4 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genes, BRCA1" by people in Profiles.
-
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2023 Sep; 201(2):257-264.
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol. 2021 05 20; 39(15):1619-1630.
-
Germline genetic contribution to the immune landscape of cancer. Immunity. 2021 02 09; 54(2):367-386.e8.
-
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2403-2415.
-
A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2020 02; 22(2):407-415.
-
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
-
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 07 25; 381(4):317-327.
-
Cancer susceptibility gene mutations in type I and II endometrial cancer. Gynecol Oncol. 2019 01; 152(1):20-25.